APA Alıntı

Castellsagué, X., Muñoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., . . . Saah, A. (2011). End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Nature Publishing Group.

Chicago Stili Alıntı

Castellsagué, X., et al. End-of-study Safety, Immunogenicity, and Efficacy of Quadrivalent HPV (types 6, 11, 16, 18) Recombinant Vaccine in Adult Women 24–45 Years of Age. Nature Publishing Group, 2011.

MLA Alıntı

Castellsagué, X., et al. End-of-study Safety, Immunogenicity, and Efficacy of Quadrivalent HPV (types 6, 11, 16, 18) Recombinant Vaccine in Adult Women 24–45 Years of Age. Nature Publishing Group, 2011.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..